New Malaria Vaccine R21/Matrix-M Rolled Out in Africa
| Category | Details |
|---|---|
| Vaccine Name | R21/Matrix-M |
| Developed By | Serum Institute of India and University of Oxford |
| Roll-out Location | Africa |
| First Country to Administer | Cote d'Ivoire (first in West Africa) |
| Approval | Approved by the World Health Organization (WHO) in 2023 |
| Effectiveness | Highly effective and affordable |
| Production | Low-dose, quick, and scalable production |
| Doses Produced | 25 million doses |
| Annual Production Capacity | 100 million doses |
| Current Roll-out Target | 250,000 children (23 months and older) in 16 regions of Cote d'Ivoire |
| Total Doses Sent to Africa | 656,600 doses |
| Authorized Countries | Ghana, Nigeria, Burkina Faso, Central African Republic |
| Key Statements | - Adar Poonawalla (Serum Institute CEO): Commitment to produce 100 million doses for affordable access. - Professor Adrian Hill (Oxford): Marks a new era in malaria control. - John C. Jacobs (Novavax CEO): An important weapon to prevent malaria's devastating impact. |